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To the Editor: Varicose vein 
sclerotherapy is a commonly per-
formed cosmetic surgical procedure 
in which a sclerosing agent is injected 
into small varicose veins of the leg 
by using small gauge needles. It is 
regarded as a minor, safe procedure, 
usually performed in an ofﬁ  ce clinic 
(1). We describe a cluster of infections 
with group A Streptococcus spp. as-
sociated with throat carriage in a cos-
metic surgeon.
In early December 2006, 3 pa-
tients were seen over a 10-day period 
at Geelong Hospital with infections 
following varicose vein sclerotherapy. 
All patients had undergone varicose 
vein sclerotherapy with polidocanol 
(Laurath-9; Aethoxysklerol, BSN 
Medical, Mount Waverley, Victoria, 
Australia) at a clinic of a single cos-
metic surgeon. The index patient (pa-
tient A) had toxic shock syndrome and 
necrotizing fasciitis of the treated legs. 
The 2 other patients (patients C and D) 
had multifocal cellulitis directly corre-
lating to the injection sites. The time 
between sclerotherapy and disease on-
set was 1–2 days.
A case-patient was deﬁ  ned as a 
patient who had undergone sclerother-
apy at the clinic and subsequently had 
infection directly related to the site 
of sclerosant injection. Events were 
dated from the day on which the index 
patient had her surgical procedure. We 
reviewed clinic notes and infection 
control procedures in conjunction with 
the Department of Human Services 
of the State Government of Victoria, 
Australia. Specimens, where avail-
able, were collected for culture from 
patients by the treating clinicians. A 
throat swab was taken from the cos-
metic surgeon. Specimens were trans-
ported and cultured by using standard 
methods.
During the outbreak period, 44 pa-
tients had vein sclerotherapy with 3% 
polidocanol at the cosmetic surgeon’s 
clinic. In addition to the 3 patients 
identiﬁ  ed on admission to hospital, a 
fourth patient (patient B) sought treat-
ment from her general practitioner 
for medical care for a postprocedure 
infection. All patients had procedures 
on day 1 or day 7 (Figure); patients A 
and B were seen consecutively on day 
1, and 2 patients were treated between 
patients C and D on day 7.
Patient A required surgical de-
bridement, intravenous antimicrobial 
drugs, intensive care, and hyperbaric 
oxygen therapy. Intraoperative speci-
mens taken from her during debride-
ment cultured group A Streptococcus 
spp. Patients B, C, and D had cellu-
litis, but no specimens suitable for 
microbiologic diagnosis of cellulitis 
were taken for culture. Patient B was 
treated with oral antimicrobial agents 
as an outpatient. Patient C was admit-
ted to hospital for intravenous antimi-
crobial therapy, and patient D showed 
no improvement on oral antimicrobial 
therapy as an outpatient and was sub-
sequently admitted to hospital for in-
travenous antimicrobial agents.
Group A Streptococcus spp. was 
isolated from a throat swab taken on 
day 16 from the cosmetic surgeon. 
He reported no upper respiratory tract 
infection symptoms before the out-
break. He also reported that antisep-
tic skin preparation was not routinely 
used during the procedures; nor were 
gloves used. However, alcohol hand 
rubs were used between patients. The 
surgeon had not changed his infection 
control procedures recently and had 
not been aware of any infective com-
plications previously. Environmental 
surface swabs taken on day 14 from 
3 different areas (procedural trolley, 
surgical spotlight, and examination 
couch) in the clinic during the assess-
ment yielded no pathogenic organisms. 
The infection control assessment team 
noted overall cleaning, disinfection, 
and hand hygiene to be inadequate. 
Decolonization of the surgeon 
was performed by using rifampin 
600 mg daily and amoxicillin 500 
Figure. Days of procedures for infected and noninfected patients and their ﬁ  rst manifestations 
of infection. , uninfected; , infected; Δ, patients A and B seen with infection; Ο, patient C 
seen with infection; and ×, patient D seen with infection.
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ing which time the surgeon suspended 
surgical procedures. Recommenda-
tions were made regarding infection 
prevention practices; these were un-
dertaken by the surgeon.
Although soft tissue infection fol-
lowing sclerotherapy may be under-
reported, large case series have not 
noted this complication in the past 
(2,3); this ﬁ   nding suggests that any 
soft tissue infection following sclero-
therapy should be investigated. These 
cases highlight the need for vigilance 
when considering infection control for 
minor procedures that take place out-
side of the support of hospital-based 
infection control services. 
Soft tissue infections as com-
plications following varicose vein 
sclerotherapy appear to be rare (1–3). 
The Australian Aethoxysklerol study 
reported no cellulitis in 16,804 legs 
injected with the sclerosing agent, and 
superﬁ  cial thrombophlebitis occurred 
at a rate of 0.08% at 2-year review 
(2). Likewise, a multicenter registry 
with 22 European phlebology clinics 
reported no cellulitis or necrotizing 
fasciitis in 12,173 sessions (3). 
Similarly, surgical site infections 
with Group A Streptococcus spp. are 
uncommon. A multicenter survey of 72 
centers worldwide reported all β-he-
molytic Streptococcus spp. (including 
group A and group G) accounted for 
<5% of infections (4), while surveil-
lance in the 1990s by Centers for Dis-
ease Control and Prevention reported 
<1% of all surgical wound infections 
was caused by group A Streptococcus 
spp. (5). A Canadian study reported 
invasive group A Streptococcus infec-
tions following surgery in 1.1 cases 
per 100,000 admissions (6). Outbreaks 
have been infrequently described (5,7–
10), and sources of colonization range 
from throat to anus and vagina. 
Acknowledgments
We thank Rosemary Lester and Mi-
chelle Cullen for their input.
Hiu-Tat Chan,* Jillian Low,† 
Lorraine Wilson,† 
Owen C Harris,* 
Allen C Cheng,† 
and Eugene Athan†
*St. John of God Pathology, Geelong, Vic-
toria, Australia, and †Barwon Health, Gee-
long, Victoria, Australia
References 
    1.    Puissegur Lupo ML. Sclerotherapy: re-
view of results and complications in 
200 patients. J Dermatol Surg Oncol. 
1989;15:214–9.
  2.  Conrad P, Malouf GM, Stacey MC. The 
Australian polidocanol (aethoxysklerol) 
study: results at 2 years. Dermatol Surg. 
1995;21:334–6.
  3.   Guex JJ, Allaert FA, Gillet JL, Chleir F. 
Immediate and midterm complications of 
sclerotherapy: report of a prospective mul-
ticenter registry of 12,173 sclerotherapy 
sessions. Dermatol Surg. 2005;31:123–8.
  4.   Koontz FP. Trends in post-operative infec-
tions by Gram-positive bacteria. Int J Anti-
microb Agents. 2000;16(Suppl 1):S35–7.
  5.   Mastro TD, Farley TA, Elliott JA, Facklam 
RR, Perks JR, Hadler JL, et al. An out-
break of surgical-wound infections due 
to group A Streptococcus carried on the 
scalp. N Engl J Med. 1990;323:968–72.
  6.   Daneman N, McGeer A, Low DE, Tyrrell 
G, Simor AE, McArthur M, et al. Hospi-
tal-acquired invasive group A streptococ-
cal infections in Ontario, Canada, 1992–
2000. Clin Infect Dis. 2005;41:334–42.
    7.    Kolmos HJ, Svendsen RN, Nielsen SV. 
The surgical team as a source of post-
operative wound infections caused by 
Streptococcus pyogenes. J Hosp Infect. 
1997;35:207–14.
  8.   Viglionese A, Nottebart VF, Bodman HA, 
Platt R. Recurrent group A streptococcal 
carriage in a health care worker associated 
with widely separated nosocomial out-
breaks. Am J Med. 1991;91:329S–33S.
  9.   Paul SM, Genese C, Spitalny K. Postoper-
ative group A beta-hemolytic Streptococ-
cus outbreak with the pathogen traced to 
a member of a healthcare worker’s house-
hold. Infect Control Hosp Epidemiol. 
1990;11:643–6.
10.   Schaffner W, Lefkowitz LB Jr, Goodman 
JS, Koenig MG. Hospital outbreak of in-
fections with group A streptococci traced 
to an asymptomatic anal carrier. N Engl J 
Med. 1969;280:1224–5.
Address for correspondence: Eugene Athan, 
Barwon Health, PO Box 281 Geelong 





To the Editor: Streptococcus suis 
is an important zoonotic pathogen for 
swine and humans. Among 33 sero-
types, serotype 2 is more frequently 
isolated from diseased pigs than other 
serotypes (1). However, not all sero-
type 2 strains are virulent, and degree 
of virulence varies among strains (2). 
Previous studies have reported sev-
eral S. suis putative virulence factors, 
including the polysaccharide capsule, 
the muramidase-released protein, the 
extracellular factor, and suilysin (3–5). 
Some of these factors have been used 
as virulence-associated markers, and 
the association of the factors of S. suis 
isolates with virulence or clinical back-
ground has been suggested in Europe 
(2,5). However, because many viru-
lent isolates lacking these factors have 
also been isolated from clinical cases 
in Canada (6), they cannot be used as 
virulence markers in North America.
Recent analysis of S. suis iso-
lates by multilocus sequence typing 
(MLST) suggested the association of 
some clonal groups with particular 
clinical manifestations. That is, most 
invasive isolates belonged to the se-
quence type (ST) 1 complex, while the 
ST27 and ST87 complexes were found 
to include a higher proportion of lung 
isolates (7). Although S. suis has been 
prevalent worldwide, the geographic 
location of the isolates used so far was 
mainly Europe, North America, and 
East Asia (7–9). Moreover, the clonal 
association with virulence of S. suis 
has been discussed mainly on the ba-
sis of clinical and experimental data 
in swine (7). In this report, to broaden 
understanding of the population struc-
ture of S. suis as a zoonotic agent, we 
characterize 20 S. suis isolates (Table) 
recovered from humans in Thailand in 
1998–2002.
Serotyping by coagglutination 
tests showed that 19 of the 20 isolates 
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